Dornase alfa for patients with cystic fibrosis: a review of the clinical efficacy and cost-effectiveness
CADTH
Record ID 32014000134
English
Authors' recommendations:
Dornase alfa appears to be effective in improving lung function among patients with CF when compared to placebo. There was no evidence of the comparative efficacy of dornase alfa and ivacaftor for the treatment of CF. With a limited amount of evidence, the cost effectiveness of dornase alfa for the treatment of CF remains to be established.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/jul-2013/RC0462%20Dornase%20Alfa%20for%20Cystic%20Fibrosis%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Deoxyribonuclease I
- Cystic Fibrosis
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.